Back to News
Market Impact: 0.35
Novavax Gains $125 Mln Payment As Sanofi Begins Phase 3 Combination Vaccine Trial; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Novavax said it earned a $125 million milestone payment after Sanofi initiated a Phase 3 influenza-COVID-19 combination vaccine trial in Europe. The trial is evaluating Novavax's COVID-19 vaccine, Nuvaxovid.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
NVAX0.60
SNY0.10
More News
- We’re downgrading Alphabet after its rough quarter. Here’s where we’d buy again
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Alphabet’s stock has worst day in over 20 years, dragging the S&P 500 to first loss in four days
- PC chip plunge wipes out a quarter of Intel’s value
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks